Cantor Fitzgerald Estimates 89bio FY2025 Earnings

89bio, Inc. (NASDAQ:ETNB) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for 89bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings per share of ($2.44) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $29.00 price objective on the stock. The consensus estimate for 89bio’s current full-year earnings is ($3.22) per share.

ETNB has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of 89bio in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of 89bio in a research note on Saturday, January 18th. Finally, Raymond James upgraded 89bio to a “strong-buy” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

89bio Stock Up 3.0 %

Shares of NASDAQ:ETNB opened at $7.13 on Thursday. The firm has a 50 day simple moving average of $7.76 and a 200 day simple moving average of $8.19. 89bio has a 52 week low of $5.99 and a 52 week high of $16.63. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.66 and a current ratio of 11.66. The company has a market cap of $756.71 million, a PE ratio of -2.45 and a beta of 1.14.

Hedge Funds Weigh In On 89bio

Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its stake in shares of 89bio by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 15,158,218 shares of the company’s stock worth $112,140,000 after acquiring an additional 1,882,108 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in 89bio in the 3rd quarter worth approximately $5,631,000. Westfield Capital Management Co. LP boosted its position in 89bio by 29.6% during the third quarter. Westfield Capital Management Co. LP now owns 3,006,038 shares of the company’s stock worth $22,245,000 after purchasing an additional 686,673 shares during the period. Walleye Capital LLC raised its position in shares of 89bio by 1,232.2% in the third quarter. Walleye Capital LLC now owns 435,298 shares of the company’s stock valued at $3,221,000 after purchasing an additional 402,624 shares during the period. Finally, Exome Asset Management LLC bought a new position in shares of 89bio in the third quarter valued at approximately $2,224,000.

Insiders Place Their Bets

In other 89bio news, CEO Rohan Palekar purchased 10,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were bought at an average price of $8.35 per share, for a total transaction of $83,500.00. Following the purchase, the chief executive officer now directly owns 466,236 shares in the company, valued at $3,893,070.60. This trade represents a 2.19 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Quoc Le-Nguyen sold 10,963 shares of 89bio stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $6.49, for a total transaction of $71,149.87. Following the completion of the sale, the insider now directly owns 271,833 shares of the company’s stock, valued at approximately $1,764,196.17. The trade was a 3.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have bought a total of 30,000 shares of company stock valued at $235,700 in the last three months. Insiders own 2.80% of the company’s stock.

89bio Company Profile

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.